Abstract
Abstract Glioblastoma is the most common and dangerous in primary brain tumors. Recent success in cancer immunotherapy is considered a breakthrough in cancer treatment. RCH-2, a phytocompound isolated from Larrea tridentata, is a transcriptional inhibitor of the Sp1 transcription factor. RCH-2 combined with different chemotherapeutic drugs also shows an excellent synergistic effect for cancer therapy in glioblastoma. RCH-2 effectively inhibits tumor growth in vivo, but less RCH-2 accumulated in the tumor area. RCH-2 might trigger an immune response to help tumor suppression. In this study, glioblastoma tumor-bearing mice were treated with RCH-2 daily by oral administration. Their cytokines and anti-tumor antibodies in sera were analyzed. Results showed that RCH-2 induced Th2 cytokines and promoted anti-tumor antibody production that efficiently induced antibody-dependent cell-mediated cytotoxicity (ADCC) to kill tumor cells. Our finding indicated that RCH-2 could induce more anti-tumor antibodies to efficiently target the tumor cell and trigger NK-mediated cell lysis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
